
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7294602/publications.pdf Version: 2024-02-01



ΔΜΑΠΟ ΔΝΠΡΑΘς

#	Article	IF	CITATIONS
1	COVID-19 in solid organ transplant recipients: A single-center case series from Spain. American Journal of Transplantation, 2020, 20, 1849-1858.	4.7	358
2	Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Kidney International, 1995, 47, 1419-1425.	5.2	168
3	Long-Term Beneficial Effects of Angiotensin-Converting Enzyme Inhibition in Patients With Nephrotic Proteinuria. American Journal of Kidney Diseases, 1992, 20, 240-248.	1.9	133
4	Effects of Body-Weight Loss and Captopril Treatment on Proteinuria Associated with Obesity. Nephron, 1995, 70, 35-41.	1.8	128
5	Factors influencing the progression of renal damage in patients with unilateral renal agenesis and remnant kidney. Kidney International, 2005, 68, 263-270.	5.2	117
6	Cancer incidence after immunosuppressive treatment following kidney transplantation. Critical Reviews in Oncology/Hematology, 2005, 56, 71-85.	4.4	115
7	Systematic screening and treatment of asymptomatic bacteriuria in renal transplant recipients. Kidney International, 2010, 78, 774-781.	5.2	113
8	Transplantation of kidneys from donors with hepatitis C antibody into recipients with pre-transplantation anti-HCV. Kidney International, 1995, 47, 236-240.	5.2	104
9	Should Asymptomatic Bacteriuria Be Systematically Treated in Kidney Transplant Recipients? Results From a Randomized Controlled Trial. American Journal of Transplantation, 2016, 16, 2943-2953.	4.7	104
10	Long-Term Experience With Kidney Transplantation From Hepatitis C-Positive Donors Into Hepatitis C-Positive Recipients. American Journal of Transplantation, 2010, 10, 2453-2462.	4.7	96
11	Risk factors for graft loss and mortality after renal transplantation according to recipient age: a prospective multicentre study. Nephrology Dialysis Transplantation, 2012, 27, iv39-iv46.	0.7	85
12	Acute graft pyelonephritis in renal transplant recipients: incidence, risk factors and long-term outcome. Nephrology Dialysis Transplantation, 2011, 26, 1065-1073.	0.7	77
13	Nephrotic Proteinuria Without Hypoalbuminemia: Clinical Characteristics and Response to Angiotensin-Converting Enzyme Inhibition. American Journal of Kidney Diseases, 1991, 17, 330-338.	1.9	75
14	Monitoring of Immunoglobulin Levels Identifies Kidney Transplant Recipients at High Risk of Infection. American Journal of Transplantation, 2012, 12, 2763-2773.	4.7	66
15	mTOR inhibitor–associated proteinuria in kidney transplant recipients. Transplantation Reviews, 2012, 26, 27-29.	2.9	65
16	Kinetics of peripheral blood lymphocyte subpopulations predicts the occurrence of opportunistic infection after kidney transplantation. Transplant International, 2014, 27, 674-685.	1.6	65
17	Hematuria due to hypercalciuria and hyperuricosuria in adult patients. Kidney International, 1989, 36, 96-99.	5.2	62
18	Clinical Presentation and Determinants of Mortality of Invasive Pulmonary Aspergillosis in Kidney Transplant Recipients: A Multinational Cohort Study. American Journal of Transplantation, 2016, 16, 3220-3234.	4.7	57

#	Article	IF	CITATIONS
19	Monitoring of alphatorquevirus DNA levels for the prediction of immunosuppression-related complications after kidney transplantation. American Journal of Transplantation, 2019, 19, 1139-1149.	4.7	57
20	SARS-CoV-2 Infection in Hospitalized Patients With Kidney Disease. Kidney International Reports, 2020, 5, 905-909.	0.8	57
21	Glomerular diseases in patients with hepatitis C virus infection after renal transplantation. Current Opinion in Nephrology and Hypertension, 1997, 6, 511-515.	2.0	55
22	HIV infection and renal transplantation. Nephrology Dialysis Transplantation, 2011, 26, 1401-1407.	0.7	55
23	Should IFN-γ, IL-17 and IL-2 be considered predictive biomarkers of acute rejection in liver and kidney transplant? Results of a multicentric study. Clinical Immunology, 2014, 154, 141-154.	3.2	55
24	Predictors of severe COVID-19 in kidney transplant recipients in the different epidemic waves: Analysis of the Spanish Registry. American Journal of Transplantation, 2021, 21, 2573-2582.	4.7	53
25	Relaparotomy After Pancreas Transplantation: Causes and Outcomes. Transplantation Proceedings, 2009, 41, 2472-2474.	0.6	52
26	Immunosuppression induced by hepatitis C virus infection reduces acute renal-transplant rejection. Lancet, The, 1995, 346, 1497-1498.	13.7	50
27	Longitudinal profile of circulating T follicular helper lymphocytes parallels anti-HLA sensitization in renal transplant recipients. American Journal of Transplantation, 2019, 19, 89-97.	4.7	48
28	Association of thin basement membrane nephropathy with hypercalciuria, hyperuricosuria and nephrolithiasis. Kidney International, 1998, 54, 915-920.	5.2	46
29	Renal transplantation in the modern immunosuppressive era in Spain: four-year results from a multicenter database focus on post-transplant cardiovascular disease. Kidney International, 2008, 74, S94-S99.	5.2	46
30	Improved short-term outcomes of kidney transplants in controlled donation after the circulatory determination of death with the use of normothermic regional perfusion. American Journal of Transplantation, 2021, 21, 3618-3628.	4.7	46
31	Valganciclovir Preemptive Therapy for the Prevention of Cytomegalovirus Disease in High-Risk Seropositive Solid-Organ Transplant Recipients. Transplantation, 2006, 82, 30-35.	1.0	45
32	A Randomized Trial Comparing Renal Function in Older Kidney Transplant Patients Following Delayed Versus Immediate Tacrolimus Administration. Transplantation, 2009, 88, 1101-1108.	1.0	45
33	Progressive increase of resistance in Enterobacteriaceae urinary isolates from kidney transplant recipients over the past decade: narrowing of the therapeutic options. Transplant Infectious Disease, 2016, 18, 575-584.	1.7	44
34	Kidney transplantation from donors after uncontrolled circulatory death: the Spanish experience. Kidney International, 2019, 95, 420-428.	5.2	43
35	RENAL TRANSPLANT IN EXTREMELY OLD RECEPTORS. Journal of Urology, 2009, 181, 808-809.	0.4	42
36	Epidemiology, risk factors and impact on long-term pancreatic function of infection following pancreas-kidney transplantation. Clinical Microbiology and Infection, 2013, 19, 1132-1139.	6.0	42

#	Article	IF	CITATIONS
37	Risk Factors Associated With Early Invasive Pulmonary Aspergillosis in Kidney Transplant Recipients: Results From a Multinational Matched Case–Control Study. American Journal of Transplantation, 2016, 16, 2148-2157.	4.7	39
38	Kidney transplant from uncontrolled donation after circulatory death donors maintained by nECMO has long-term outcomes comparable to standard criteria donation after brain death. American Journal of Transplantation, 2019, 19, 434-447.	4.7	39
39	Fabry Nephropathy: An Evidence-Based Narrative Review. Kidney and Blood Pressure Research, 2018, 43, 406-421.	2.0	35
40	The Presence of Pretransplant Antiphospholipid Antibodies IgA Anti-β-2-Glycoprotein I as a Predictor of Graft Thrombosis After Renal Transplantation. Transplantation, 2017, 101, 597-607.	1.0	34
41	Lower Rate of Family Refusal for Organ Donation in Non–Heart-Beating Versus Brain-Dead Donors. Transplantation Proceedings, 2009, 41, 2304-2305.	0.6	33
42	Hypocomplementemia in Kidney Transplant Recipients: Impact on the Risk of Infectious Complications. American Journal of Transplantation, 2013, 13, 685-694.	4.7	33
43	Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment. Clinical Microbiology and Infection, 2019, 25, 381.e1-381.e10.	6.0	32
44	Addition of Spironolactone to Dual Blockade of Renin Angiotensin System Dramatically Reduces Severe Proteinuria in Renal Transplant Patients: An Uncontrolled Pilot Study at 6 Months. Transplantation Proceedings, 2010, 42, 2899-2901.	0.6	31
45	Association of Early Kidney Allograft Failure with Preformed IgA Antibodies to β 2-Glycoprotein I. Journal of the American Society of Nephrology: JASN, 2015, 26, 735-745.	6.1	31
46	Impact of anti-HCV direct antiviral agents on graft function and immunosuppressive drug levels in kidney transplant recipients: a call to attention in the mid-term follow-up in a single-center cohort study. Transplant International, 2018, 31, 887-899.	1.6	31
47	Monitoring of CMV-specific cell-mediated immunity with a commercial ELISA-based interferon-Î ³ release assay in kidney transplant recipients treated with antithymocyte globulin. American Journal of Transplantation, 2020, 20, 2070-2080.	4.7	30
48	Hepatitis C virus and renal transplantation. Current Opinion in Nephrology and Hypertension, 1998, 7, 177-184.	2.0	29
49	Familial microscopic hematuria caused by hypercalciuria and hyperuricosuria. American Journal of Kidney Diseases, 2000, 35, 141-145.	1.9	28
50	Harmful Effect of Preformed Anti-MICA Antibodies on Renal Allograft Evolution in Early Posttransplantation Period. Transplantation, 2013, 96, 70-78.	1.0	28
51	Discordance Between SARS-CoV-2–specific Cell-mediated and Antibody Responses Elicited by mRNA-1273 Vaccine in Kidney and Liver Transplant Recipients. Transplantation Direct, 2021, 7, e794.	1.6	28
52	Plasma homocysteine levels in renal transplanted patients on cyclosporine or tacrolimus therapy: effect of treatment with folic acid. Clinical Transplantation, 2000, 14, 110-114.	1.6	27
53	Comparison of Cytomegalovirus Viral Load Measure by Real-Time PCR With pp65 Antigenemia for the Diagnosis of Cytomegalovirus Disease in Solid Organ Transplant Patients. Transplantation Proceedings, 2005, 37, 4094-4096.	0.6	27
54	Policies concerning the use of kidneys from donors infected with hepatitis C virus. Nephrology Dialysis Transplantation, 2000, 15, 71-73.	0.7	27

#	Article	IF	CITATIONS
55	Multinational case-control study of risk factors for the development of late invasive pulmonary aspergillosis following kidney transplantation. Clinical Microbiology and Infection, 2018, 24, 192-198.	6.0	25
56	Efficacy and Safety of Valsartan, an Angiotensin II Receptor Antagonist, in Hypertension After Renal Transplantation: A Randomized Multicenter Study. Transplantation Proceedings, 2006, 38, 2419-2423.	0.6	23
57	Glomerulonephritis associated with hepatitis C virus infection. Current Opinion in Nephrology and Hypertension, 1999, 8, 205-211.	2.0	23
58	Posttransplant Diabetes Mellitus in Renal Allograft Recipients: A Prospective Multicenter Study at 2 Years. Transplantation Proceedings, 2006, 38, 3530-3532.	0.6	21
59	High incidence of delayed graft function in HIV-infected kidney transplant recipients. Transplant International, 2013, 26, 893-902.	1.6	21
60	Preâ€ŧransplant dialysis modality does not influence short―or longâ€ŧerm outcome in kidney transplant recipients: analysis of paired kidneys from the same deceased donor. Clinical Transplantation, 2016, 30, 1097-1107.	1.6	21
61	Ischemic Heart Disease after Renal Transplantation in Patients on Cyclosporine in Spain. Journal of the American Society of Nephrology: JASN, 2006, 17, S286-S290.	6.1	20
62	Effect of longâ€ŧerm prophylaxis in the development of cytomegalovirusâ€specific Tâ€cell immunity in D+/Râ^' solid organ transplant recipients. Transplant Infectious Disease, 2015, 17, 637-646.	1.7	20
63	Helical computed tomography angiography is the most efficient test to assess vascular calcifications in the iliac arterial sector in renal transplant candidates. Transplantation Proceedings, 2003, 35, 1682-1683.	0.6	19
64	Tocilizumab use in Kidney Transplant Patients with COVIDâ€19. Clinical Transplantation, 2020, 34, e14072.	1.6	19
65	Compative Study of Bladder Versus Enteric Drainage in Pancreas Transplantation. Transplantation Proceedings, 2009, 41, 2466-2468.	0.6	18
66	Renal transplantation in patients with hepatitis C virus antibody. A long national experience. CKJ: Clinical Kidney Journal, 2010, 3, ii41-ii46.	2.9	18
67	Epstein-Barr Virus DNAemia Is an Early Surrogate Marker of the Net State of Immunosuppresion in Solid Organ Transplant Recipients. Transplantation, 2013, 95, 688-693.	1.0	18
68	Acute renal failure after liver transplantation in patients treated with cyclosporine. Transplantation Proceedings, 1992, 24, 126-7.	0.6	18
69	Urological Complications After Simultaneous Pancreas-Kidney Transplantation. Transplantation Proceedings, 2009, 41, 2457-2459.	0.6	17
70	Treatment with calcimimetics in kidney transplantation. Transplantation Reviews, 2010, 24, 79-88.	2.9	17
71	SARS-CoV-2-Specific Cell-Mediated Immunity in Kidney Transplant Recipients Recovered from COVID-19 Transplantation, 2021, Publish Ahead of Print, 1372-1380.	1.0	17
72	A new strategy of delayed longâ€ŧerm prophylaxis could prevent cytomegalovirus disease in (D+/Râ^') solid organ transplant recipients. Clinical Transplantation, 2009, 23, 666-671.	1.6	16

#	Article	IF	CITATIONS
73	Extended-Release Tacrolimus Therapy in De Novo Kidney Transplant Recipients: Single-Center Experience. Transplantation Proceedings, 2010, 42, 3034-3037.	0.6	16
74	Donation after cardiac death: results of the <scp>SUMMA</scp> 112 – <scp>H</scp> ospital 12 de <scp>O</scp> ctubre <scp>P</scp> rogram. Clinical Transplantation, 2013, 27, 283-288.	1.6	16
75	Early kinetics of Torque Teno virus DNA load and BK polyomavirus viremia after kidney transplantation. Transplant Infectious Disease, 2020, 22, e13240.	1.7	16
76	Influence of Dialysis Modality on Complications and Patient and Graft Survival After Pancreas-Kidney Transplantation. Transplantation Proceedings, 2008, 40, 2999-3000.	0.6	15
77	Cardiovascular Events After Simultaneous Pancreas-Kidney Transplantation. Transplantation Proceedings, 2010, 42, 2981-2983.	0.6	15
78	Uncontrolled donation after circulatory death. Current Opinion in Organ Transplantation, 2019, 24, 358-363.	1.6	15
79	Oral fosfomycin for the treatment of lower urinary tract infections among kidney transplant recipients—Results of a Spanish multicenter cohort. American Journal of Transplantation, 2020, 20, 451-462.	4.7	15
80	Results of kidney transplantation in recipients over 70 years of age: experience at a single center. Transplantation Proceedings, 2003, 35, 1675-1676.	0.6	14
81	Potential role of post-transplant hypogammaglobulinemia in the risk of Clostridium difficile infection after kidney transplantation: a case–control study. Infection, 2015, 43, 413-422.	4.7	14
82	Kidney transplantation in the extremely elderly from extremely aged deceased donors: a kidney for each age. Nephrology Dialysis Transplantation, 2020, 35, 687-696.	0.7	14
83	A randomized trial of basiliximab with three different patterns of cyclosporin A initiation in renal transplant from expanded criteria donors and at high risk of delayed graft function. Clinical Transplantation, 2009, 23, 23-32.	1.6	13
84	Serum <scp>sCD</scp> 30: A promising biomarker for predicting the risk of bacterial infection after kidney transplantation. Transplant Infectious Disease, 2017, 19, e12668.	1.7	13
85	Pretransplant IgA-Anti-Beta 2 Glycoprotein I Antibodies As a Predictor of Early Graft Thrombosis after Renal Transplantation in the Clinical Practice: A Multicenter and Prospective Study. Frontiers in Immunology, 2018, 9, 468.	4.8	13
86	Imbalance favoring follicular helper T cells over IL10+ regulatory B cells is detrimental for the kidney allograft. Kidney International, 2020, 98, 732-743.	5.2	13
87	Kidneys From Elderly Deceased Donors Discarded for Transplantation. Transplantation Proceedings, 2009, 41, 2379-2381.	0.6	12
88	Clinical Implications of Proteinuria in Renal Transplant Recipients Switching to Rapamycin for Chronic Allograft Dysfunction. Transplantation Proceedings, 2009, 41, 2348-2350.	0.6	12
89	Renal Function and NODM in <i>De Novo</i> Renal Transplant Recipients Treated with Standard and Reduced Levels of Tacrolimus in Combination with EC-MPS. Journal of Transplantation, 2012, 2012, 1-9.	0.5	12
90	Serum iron parameters in the early postâ€ŧransplant period and infection risk in kidney transplant recipients. Transplant Infectious Disease, 2013, 15, 600-611.	1.7	12

#	Article	IF	CITATIONS
91	Herpes zoster in kidney transplant recipients: protective effect of anti-cytomegalovirus prophylaxis and natural killer cell count. A single-center cohort study. Transplant International, 2018, 31, 187-197.	1.6	12
92	Fibrosing cholestatic hepatitis-like syndrome in hepatitis B virus–negative and hepatitis C virus–negative renal transplant recipients. American Journal of Kidney Diseases, 2001, 38, 640-645.	1.9	11
93	Peripheral Blood Regulatory T Cells in Long-Term Kidney Transplant Recipients. Transplantation Proceedings, 2009, 41, 2360-2362.	0.6	11
94	Survival of Patients Older Than 60 Years With Kidneys Transplanted From Spanish Expanded Criteria Donors Versus Patients Continued on Hemodialysis. Transplantation Proceedings, 2009, 41, 2376-2378.	0.6	11
95	Effect of delaying prophylaxis against CMV in D+/Râ~ solid organ transplant recipients in the development of CMV-specific cellular immunity and occurrence of late CMV disease. Journal of Infection, 2015, 71, 561-570.	3.3	11
96	Monitoring of intracellular adenosine triphosphate in CD4 ⁺ T cells to predict the occurrence of cytomegalovirus disease in kidney transplant recipients. Transplant International, 2016, 29, 1094-1105.	1.6	11
97	Number and function of circulatory helper innate lymphoid cells are unaffected by immunosuppressive drugs used in solid organ recipients – a single centre cohort study. Transplant International, 2020, 33, 402-413.	1.6	11
98	Immune risk phenotype in kidney transplant recipients: a reliable surrogate for premature immune senescence and increased susceptibility to infection?. Transplant Infectious Disease, 2016, 18, 968-970.	1.7	10
99	Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreas–kidney transplant recipients. Transplant Infectious Disease, 2009, 11, 400-404.	1.7	9
100	Results of a Living Donor Kidney Promotion Program. Transplantation Proceedings, 2010, 42, 2837-2838.	0.6	9
101	Association between baseline serum hepcidin levels and infection in kidney transplant recipients: Potential role for iron overload. Transplant Infectious Disease, 2018, 20, e12807.	1.7	9
102	Use of kidneys from anti-HCV positive donors. Transplantation Proceedings, 2001, 33, 1776-1777.	0.6	8
103	Anti-CD25 Monoclonal Antibody Sequential Immunosuppressive Induction Therapy in Renal Transplants With High Risk of Delayed Graft Function. Transplantation Proceedings, 2005, 37, 3736-3737.	0.6	8
104	Kidney Transplantation Outcomes in HIV Infection: The European Experience. American Journal of Transplantation, 2011, 11, 635-636.	4.7	8
105	Infection Risk in Kidney Transplantation From Uncontrolled Donation After Circulatory Death Donors. Transplantation Proceedings, 2013, 45, 1335-1338.	0.6	8
106	Influence of Age and HLA Alleles on the CMV-Specific Cell-Mediated Immunity Among CMV-Seropositive Kidney Transplant Candidates. American Journal of Transplantation, 2015, 15, 2525-2526.	4.7	8
107	Impact of Left Ventricular Dysfunction on Renal Transplant Survival: Study of Paired Kidneys From the Same Donor. Transplantation Proceedings, 2015, 47, 70-72.	0.6	8
108	Preemptive kidney transplantation in elderly recipients with kidneys discarded of very old donors: A good alternative. Nefrologia, 2015, 35, 246-255.	0.4	8

#	Article	IF	CITATIONS
109	Experience with miltefosine for persistent or relapsing visceralÂleishmaniasis in solid organ transplant recipients: AÂcase series from Spain. Transplant Infectious Disease, 2017, 19, e12623.	1.7	8
110	Early Posttransplant Mobilization of Monocytic Myeloid-derived Suppressor Cell Correlates With Increase in Soluble Immunosuppressive Factors and Predicts Cancer in Kidney Recipients. Transplantation, 2020, 104, 2599-2608.	1.0	8
111	Tubular Dysfunction in Nephrotic Syndrome: Incidence and Prognostic Implications. Nephrology Dialysis Transplantation, 1991, 6, 683-688.	0.7	7
112	Vitamin D deficiency and infection risk in kidney transplant recipients: A single enter cohort study. Transplant Infectious Disease, 2018, 20, e12988.	1.7	7
113	Malignancies in Deceased Organ Donors: The Spanish Experience. Transplantation, 2022, 106, 1814-1823.	1.0	7
114	Should we be using kidneys from hepatitis C virus-infected donors?. Current Opinion in Nephrology and Hypertension, 2011, 20, 599-604.	2.0	6
115	Impact of squaleneâ€based adjuvanted influenza vaccination on graft outcome in kidney transplant recipients. Transplant Infectious Disease, 2015, 17, 314-321.	1.7	6
116	Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients. Kidney International Reports, 2018, 3, 122-132.	0.8	6
117	Idiopathic dialysis ascites in the nineties: Resolution after renal transplantation. American Journal of Kidney Diseases, 1995, 26, 668-670.	1.9	5
118	Renal Transplantation in Emigrants From Africa in Spain: Similar Results but Different Infectious Profile Compared With Spanish People. Transplantation Proceedings, 2009, 41, 2363-2365.	0.6	5
119	Renal Transplantation from Donors with a Positive Serology for Hepatitis C. Contributions To Nephrology, 2012, 176, 117-129.	1.1	5
120	Circulatory follicular helper T lymphocytes associate with lower incidence of CMV infection in kidney transplant recipients. American Journal of Transplantation, 2021, 21, 3946-3957.	4.7	5
121	Entericâ€coated mycophenolate sodium in <i>de novo</i> and maintenance kidney–pancreas transplant recipients. Clinical Transplantation, 2012, 26, 424-431.	1.6	4
122	Assessing the Risk of De Novo Malignancy in Kidney Transplant Recipients. Transplantation, 2014, 98, e36-e37.	1.0	4
123	Detection of BK polyomavirus genotypes to predict the development of BK polyomavirusâ€associated complications in kidney transplant recipients: A retrospective analysis. Transplant Infectious Disease, 2021, 23, e13615.	1.7	4
124	Efficacy and Safety of Oral Fosfomycin for Asymptomatic Bacteriuria in Kidney Transplant Recipients: Results from a Spanish Multicenter Cohort. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	4
125	A disproportionately greater body weight of the recipient in regards to the donor causes chronic graft nephropathy. A study of paired kidneys. Nephrology Dialysis Transplantation, 2004, 19, iii21-iii25.	0.7	3
126	Low 25-hydroxyvitamin D Levels and the Risk of Late CMV Infection After Kidney Transplantation: Role for CMV-specific Mediated Immunity. Transplantation, 2019, 103, e216-e217.	1.0	3

#	Article	IF	CITATIONS
127	Variations in Circulating Active MMP-9 Levels during Renal Replacement Therapy. Biomolecules, 2020, 10, 505.	4.0	3
128	Pericarditis secondary to COVID-19 infection in a kidney transplant recipient. Nefrologia, 2021, 41, 349-351.	0.4	3
129	Human pegivirus type 1 infection in kidney transplant recipients: Replication kinetics and clinical correlates. Transplant Infectious Disease, 2022, 24, .	1.7	3
130	The early impact of mycophenolate mofetil in combination with steroids and cyclosporine neoral after renal transplantation: a six-month analysis. Transplantation Proceedings, 1999, 31, 2265-2266.	0.6	2
131	Role of immunosuppressive treatments based on mycophenolate mofetil in posttransplantation renal surgical complications. Transplantation Proceedings, 2002, 34, 96.	0.6	2
132	Post-transplant hypocomplementemia: A novel marker of cardiovascular risk in kidney transplant recipients?. Atherosclerosis, 2018, 269, 204-210.	0.8	2
133	Kidney Transplantation from Uncontrolled Donation after Circulatory Death, our Outcomes Compared to Donation after Brain Death after Very Long Time. Transplantation, 2018, 102, S413.	1.0	2
134	A New Clinical and Immunovirological Score for Predicting the Risk of Late Severe Infection in Solid Organ Transplant Recipients: The CLIV Score. Journal of Infectious Diseases, 2020, 222, 479-487.	4.0	2
135	CMV infection, valganciclovir exposure, and the risk of BK viremia and associated nephropathy after kidney transplantation: Is there a link?. Transplant Infectious Disease, 2021, 23, e13597.	1.7	2
136	Fluconazole versus micafungin for initial antifungal prophylaxis against <i>Candida</i> in pancreas transplant recipients: A comparative study of two consecutive periods. Mycoses, 2022, 65, 517-525.	4.0	2
137	Enterococcal infection in kidney transplant recipients in a setting of low prevalence of vancomycin resistance. Transplant Infectious Disease, 2014, 16, 692-695.	1.7	1
138	PReFiNe project: strategic plan to improve knowledge & recognition of Fabry disease among Spanish nephrologists. Molecular Genetics and Metabolism, 2017, 120, S41.	1.1	1
139	Cytomegalovirus Exposure and the Risk of Overall Infection After Kidney Transplantation: A Cohort Study on the Indirect Effects Attributable to Viral Replication. Transplant International, 2021, 35, 10273.	1.6	1
140	Role of cytomegalovirus infection after kidney transplantation on the subsequent risk of atherosclerotic and thrombotic events. Atherosclerosis Plus, 2022, 48, 37-46.	0.7	1
141	MO976: Recurrence of Immune Complex And Complement-Mediated Membranoproliferative Glomerulonephritis in Kidney Transplantation. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	1
142	Results of renal re-transplant in Spain (1990-2002). CKJ: Clinical Kidney Journal, 2010, 3, ii37-ii40.	2.9	0
143	2197 NON-HEART-BEATING DONORS (TYPE I AND II MAASTRICHT CATEGORY): RESULTS OF OUR PROGRAM. Journal of Urology, 2011, 185, .	0.4	Ο
144	Non-Heart Beating Donor Kidney Transplantation Is not Associated with An Increased Risk of Post-Transplant Infection. Transplantation, 2012, 94, 552.	1.0	0

#	Article	IF	CITATIONS
145	The Impact of High Steroid Doses in Patients with Post- Transplant Membranous Glomerulonephritis Associated or not with Hepatitis C Virus Infection. Transplantation, 2012, 94, 918.	1.0	0
146	SP840RELATIONSHIP BETWEEN PRE-TRANSPLANT BODY COMPOSITION AND RENAL POST-TRANSPLANT EVOLUTION. Nephrology Dialysis Transplantation, 2015, 30, iii654-iii654.	0.7	0
147	FP723RESULTS OF KIDNEY TRANSPLANTATION IN VERY OLD RECIPIENTS. Nephrology Dialysis Transplantation, 2018, 33, i290-i290.	0.7	0
148	The Use of Sofosbuvir (SOF)-containing Direct Antiviral Agents (DAA)-based Regimens Requires Increase in Tacrolimus (Tac) Doses in Kidney Transplant (KT) Recipients with Hepatitis C Virus (HCV) Infection. Transplantation, 2018, 102, S228.	1.0	0
149	Successful Treatment of BK Nephropathy with Tacrolimus and mTOR Inhibitors. Transplantation, 2018, 102, S327.	1.0	0
150	FP712KIDNEY TRANSPLANTATION FROM UNCONTROLLED DONATION AFTER CIRCULATORY DEATH AFTER 10 YEAR OF FOLLOW-UP. Nephrology Dialysis Transplantation, 2018, 33, i285-i286.	0.7	0
151	SP753MALIGNANCY COMPLICATIONS AFTER KIDNEY TRANSPLANTATION, SHOULD WE USE INDUCTION THERAPY?. Nephrology Dialysis Transplantation, 2018, 33, i602-i602.	0.7	0
152	Results of Kidney Transplantation in Very Old Age Recipients Using Kidneys from Very Old Donors. Transplantation, 2018, 102, S159.	1.0	0
153	Helper Innate Lymphoid Cells (hILC) resist Immunosuppressive Therapy. Transplantation, 2018, 102, S283-S284.	1.0	0
154	Continuous Training of Critical Care Professional to Increase Organ Donation Rates in Yunnan Province and Guangxi Autonomous Region in China. Transplantation, 2018, 102, S810.	1.0	0
155	Cardiovascular Disease after Kidney Transplant from Uncontrolled Donation after Circulatory Death (uDCD). Transplantation, 2018, 102, S84.	1.0	0
156	Different Patterns of Risk Factors for Mortality according Recipient Age after Renal Transplantation. A Multicenter and Prospective Study at Ten Years in the Clinical Practice. Transplantation, 2018, 102, S191.	1.0	0
157	Malignancy Complications after Kidney Transplantation with Different Immunosuppression Induction Protocols. Transplantation, 2018, 102, S348.	1.0	0
158	Chronic Hypotension in Dialysis is a Prognostic Factor in the Evolution of Kidney Transplantation. Transplantation, 2018, 102, S529.	1.0	0
159	SP167RECURRENCE OF MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS AFTER KIDNEY TRANSPLANTATION. Nephrology Dialysis Transplantation, 2018, 33, i400-i400.	0.7	0
160	Analysis of the Incidence of Brain Death per Functioning Ventilator in the Intensive Care Units of a General Hospital. Transplantation, 2018, 102, S806.	1.0	0
161	Rituximab does not Prevent Focal and Segmental Glomerulosclerosis Recurrence after Renal Transplantation in Patients at Risk. Transplantation, 2018, 102, S9.	1.0	0
162	115.7: DTI Foundation collaboration with China: An educational and cooperation program Transplantation, 2019, 103, S4-S5.	1.0	0

#	ARTICLE	IF	CITATIONS
163	MicroangiopatÃa trombótica como recidiva de sÃndrome antifosfolÃpido en trasplante renal. Nefrologia, 2020, 40, 108-110.	0.4	0
164	Long-term plasmapheresis therapy in the management of focal segmental glomerulosclerosis recurrence after kidney transplantation. Transfusion and Apheresis Science, 2021, 60, 103046.	1.0	0
165	The impact of darbepoetin alfa in early post-transplant anaemia management: retrospective exploratory study. Nefrologia, 2013, 33, 107-15.	0.4	Ο